ABSTRACT
Intro: Uptake of SARS-CoV-2 rapid antigen tests (RATs) for self-testing has been high following authorisation by the Australian Therapeutic Goods Administration (TGA). However, there are no published Australian data assessing feasibility and compliance with home-based rapid antigen testing. The aim of this study was to determine the acceptability of daily rapid antigen self-testing. Method(s): We prospectively recruited a cohort of hospital employees and students from primary and secondary school to perform daily self-testing using RATs in the home over 14 consecutive days. Participants consenting to the study were supplied with 15 Roche SARS-CoV-2 Antigen Nasal Self Tests, 3 saliva swabs for self-collection for RT-PCR and were asked to record results and answer a daily survey using a smartphone application. Finding(s): 38% (26/68) of the cohort were compliant to 14 consecutive days of testing;this was significantly higher in students (71%) than hospital employees (28%). The median number of tests performed over 14 consecutive days was 11 and time to first missed test was a median 5.5 days. The most common reasons for missing days were "I forgot" (37.5%) and "too busy" (8.9%). Ease of self- nasal swabbing, self-nasal testing. performing the test and using the app were rated as comfortable/very comfortable in over 80% of the cohort. Discussion(s): Most study participants in this Australian cohort were compliant with frequent home-based RATs. By study end most participants (93.8%) found the testing process acceptable/very acceptable. There is need for further work on the cost-effectiveness and impact of self-tested RATs under a range of specific uses and conditions. Conclusion(s): This study provided valuable information on acceptability and feasibility of regular home-based testing which could be applied to other diseases. Ongoing community engagement with clear information on RATs including accuracy and use cases is important for decision-making and addressing concerns, particularly for linguistically diverse peoples.Copyright © 2023
ABSTRACT
COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first recognised in late 2019, with over 30 000 000 cases and over 1 000 000 deaths reported by the end of September 2020. SARS-CoV-2 infection is usually associated with fever, cough, coryza, dyspnoea, anosmia, headache and fatigue and may cause pneumonia and hypoxemia. An excessive/dysregulated inflammatory response may lead to lung damage including acute respiratory distress syndrome (ARDS), coagulopathy and other complications. Mortality amongst hospitalised patients is higher in those needing intensive care. In Australia over 27 000 cases with 882 deaths had been reported by 30 September, most in Victoria. Two therapies have proven beneficial in treatment of hospitalised patients in expedited randomised placebo-controlled trials and are now in widespread use. Dexamethasone improved survival of those requiring respiratory support and the antiviral agent remdesivir decreased time to recovery in mild-moderate disease. Remdesivir was authorised by the Australian Therapeutic Goods Administration in July 2020. Over 200 other therapeutics are being tested for COVID-19 in more than 2000 clinical trials, and many more agents are in preclinical development. We review the evidence for some of the candidates for therapy in COVID-19. © 2020 CSIRO. All rights reserved.